vs
CapsoVision, Inc（CV）与Lakeside Holding Ltd（LSH）财务数据对比。点击上方公司名可切换其他公司
Lakeside Holding Ltd的季度营收约是CapsoVision, Inc的2.0倍（$7.0M vs $3.5M），Lakeside Holding Ltd净利率更高（-22.6% vs -223.9%，领先201.3%）
CapsoVision, Inc.是一家医疗科技企业，专注研发、生产先进胶囊内窥镜系统及配套诊断解决方案，旗下非侵入式胃肠道成像产品供应全球多地的医院、消化科诊所及医疗专业人员，助力提升消化道疾病检测准确率与患者诊疗体验。
莱克赛德出版社是位于美国芝加哥的出版品牌，由RR唐纳利公司运营。该社除了出版高品质书籍外，还承印邮购目录、电话号码簿、百科全书与广告宣传品，最为人熟知的是为芝加哥卡克斯顿俱乐部出版的高端版本，以及经典重印丛书《莱克赛德经典》。
CV vs LSH — 直观对比
营收规模更大
LSH
是对方的2.0倍
$3.5M
净利率更高
LSH
高出201.3%
-223.9%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.5M | $7.0M |
| 净利润 | $-7.9M | $-1.6M |
| 毛利率 | 54.1% | 27.2% |
| 营业利润率 | -226.7% | -21.3% |
| 净利率 | -223.9% | -22.6% |
| 营收同比 | — | 95.0% |
| 净利润同比 | — | 18.7% |
| 每股收益（稀释后） | $-0.17 | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CVLSH
| Q4 25 | — | $7.0M | ||
| Q3 25 | $3.5M | $6.1M | ||
| Q2 25 | $3.3M | $6.3M | ||
| Q1 25 | — | $3.8M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.1M |
净利润CVLSH
| Q4 25 | — | $-1.6M | ||
| Q3 25 | $-7.9M | $-1.4M | ||
| Q2 25 | $-4.6M | $-893.1K | ||
| Q1 25 | — | $-1.1M | ||
| Q4 24 | — | $-1.9M | ||
| Q3 24 | — | $-1.3M |
毛利率CVLSH
| Q4 25 | — | 27.2% | ||
| Q3 25 | 54.1% | 18.2% | ||
| Q2 25 | 54.6% | 26.7% | ||
| Q1 25 | — | 18.8% | ||
| Q4 24 | — | -1.2% | ||
| Q3 24 | — | 12.8% |
营业利润率CVLSH
| Q4 25 | — | -21.3% | ||
| Q3 25 | -226.7% | -20.8% | ||
| Q2 25 | -140.3% | -8.9% | ||
| Q1 25 | — | -28.2% | ||
| Q4 24 | — | -55.6% | ||
| Q3 24 | — | -32.5% |
净利率CVLSH
| Q4 25 | — | -22.6% | ||
| Q3 25 | -223.9% | -22.2% | ||
| Q2 25 | -139.5% | -14.2% | ||
| Q1 25 | — | -28.2% | ||
| Q4 24 | — | -54.1% | ||
| Q3 24 | — | -32.7% |
每股收益（稀释后）CVLSH
| Q4 25 | — | $-0.08 | ||
| Q3 25 | $-0.17 | $-0.09 | ||
| Q2 25 | $-2.02 | $-0.11 | ||
| Q1 25 | — | $-0.14 | ||
| Q4 24 | — | $-0.26 | ||
| Q3 24 | — | $-0.18 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $1.6M |
| 总债务越低越好 | — | $2.4M |
| 股东权益账面价值 | $20.4M | $12.2M |
| 总资产 | $25.7M | $24.3M |
| 负债/权益比越低杠杆越低 | — | 0.20× |
8季度趋势，按日历期对齐
现金及短期投资CVLSH
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $4.5M | ||
| Q2 25 | — | $5.0M | ||
| Q1 25 | — | $1.5M | ||
| Q4 24 | — | $1.1M | ||
| Q3 24 | — | $2.7M |
总债务CVLSH
| Q4 25 | — | $2.4M | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | — | $1.4M | ||
| Q1 25 | — | $774.2K | ||
| Q4 24 | — | $784.8K | ||
| Q3 24 | — | $589.9K |
股东权益CVLSH
| Q4 25 | — | $12.2M | ||
| Q3 25 | $20.4M | $7.0M | ||
| Q2 25 | $-139.0M | $2.8M | ||
| Q1 25 | — | $749.8K | ||
| Q4 24 | — | $1.6M | ||
| Q3 24 | — | $3.6M |
总资产CVLSH
| Q4 25 | — | $24.3M | ||
| Q3 25 | $25.7M | $18.6M | ||
| Q2 25 | $9.5M | $14.4M | ||
| Q1 25 | — | $9.9M | ||
| Q4 24 | — | $9.8M | ||
| Q3 24 | — | $10.8M |
负债/权益比CVLSH
| Q4 25 | — | 0.20× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 0.48× | ||
| Q1 25 | — | 1.03× | ||
| Q4 24 | — | 0.48× | ||
| Q3 24 | — | 0.16× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.7M | $-453.5K |
| 自由现金流经营现金流 - 资本支出 | $-5.7M | — |
| 自由现金流率自由现金流/营收 | -160.5% | — |
| 资本支出强度资本支出/营收 | 0.3% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CVLSH
| Q4 25 | — | $-453.5K | ||
| Q3 25 | $-5.7M | $-4.0M | ||
| Q2 25 | $-9.5M | $-483.7K | ||
| Q1 25 | — | $-238.3K | ||
| Q4 24 | — | $-530.2K | ||
| Q3 24 | — | $-1.4M |
自由现金流CVLSH
| Q4 25 | — | — | ||
| Q3 25 | $-5.7M | — | ||
| Q2 25 | $-9.6M | $-497.4K | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-560.5K | ||
| Q3 24 | — | $-1.4M |
自由现金流率CVLSH
| Q4 25 | — | — | ||
| Q3 25 | -160.5% | — | ||
| Q2 25 | -289.0% | -7.9% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -15.6% | ||
| Q3 24 | — | -34.5% |
资本支出强度CVLSH
| Q4 25 | — | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 2.1% | 0.2% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.8% | ||
| Q3 24 | — | 0.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CV
| Products | $2.5M | 71% |
| Other | $1.0M | 29% |
LSH
| Transferred Over Time | $4.6M | 65% |
| Distribution Of Pharmaceutical Products | $2.4M | 35% |
